DIPG/High Grade Glioma New Diagnosis
DIPG/High Grade Glioma New Diagnosis
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Ages: 12 Months to 21 Years
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mut ...More
CONNECT1903: A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Ages: Up to 21 Years
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with c ...More
CONNECT1906: PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Ages: 3 Year to 25 Years
This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Ea ...More
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
- Ages: 3 years to 25 years
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of ...More
GCC1949: Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
- Ages: 3 years to 21 years of age
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ ...More
Volitinib in Treating Participants with Recurrent or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma
- Ages: 6 Years to 21 Year
This phase I trial studies the best dose and side effect of volitinib in treating participants with Medulloblastoma, High-Grade Glioma or Diffuse Intrinsic Pontine Glioma that have come or does not respond to treatment. Volitinib may stop the growth of tumor cells by blocking some of the enzymes nee ...More
Contact Us
To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Medulloblastoma New Diagnosis
- Medulloblastoma Relapse / Refractory
- Low Grade Glioma New Diagnosis
- Low Grade Glioma Relapse / Refractory
- DIPG/High Grade Glioma Relapse / Refractory
- Ependymoma New Diagnosis
- Ependymoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Neurofibromatosis Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- ATRT
- Craniopharyngioma
- Germ Cell Tumor
- Choroid Plexus Tumor
- All Other Brain and Spinal Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
